Answers are grounded in this paper and cite their sources.
Although commonly used to treat patients with multiple sclerosis, DMDs were not associated with clinical improvement in children with MOG-Ab-associated disease, whereas azathioprine, mycophenolate mofetil, rituximab, and particularly intravenous immunoglobulins were associated with a reduction in relapse frequency. A correct diagnosis of relapsing MOG-Ab-associated disorders is therefore important to optimize immune treatment.
No takes yet. Share an insight, caveat, or question.
Hacohen et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: